CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia.

Chen D, Camponeschi A, Wu Q, Gerasimcik N, Li H, Shen X, Tan Y, Sjögren H, Nordlund J, Lönnerholm G, Abrahamsson J, Fogelstrand L, Mårtensson IL

Br. J. Haematol. 184 (3) 418-423 [2019-02-00; online 2018-11-28]

Our study aimed to determine the expression pattern and clinical relevance of CD99 in paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). Our findings demonstrate that high expression levels of CD99 are mainly found in high-risk BCP-ALL, e.g. BCR-ABL1 and CRLF2Re/Hi , and that high CD99 mRNA levels are strongly associated with a high frequency of relapse, high proportion of positive for minimal residual disease at day 29 and poor overall survival in paediatric cohorts, which indicate that CD99 is a potential biomarker for BCP-ALL.

NGI Uppsala (SNP&SEQ Technology Platform) [Service]

National Genomics Infrastructure [Service]

QC bibliography QC xrefs

PubMed 30484860

DOI 10.1111/bjh.15683

Crossref 10.1111/bjh.15683